# Effects of Oral Sildenafil on Mortality in Adults With PAH

Study · id `cardio:ct-nct02060487` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02060487](<https://clinicaltrials.gov/study/NCT02060487>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02060487

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 385 participants.

## Technical summary

Registry record NCT02060487. Randomized; quadruple masking; primary purpose treatment. Start 2014-09-22 (actual); primary completion 2021-02-26 (actual). Results posted on 2022-05-10.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 385 participants (enrolled count; ClinicalTrials.gov record NCT02060487, source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)
- Started: 2014-09-22 (actual) (ClinicalTrials.gov record NCT02060487, source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)
- Primary completion: 2021-02-26 (actual) (ClinicalTrials.gov record NCT02060487, source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)
- Completion: 2021-02-26 (actual) (ClinicalTrials.gov record NCT02060487, source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)
- Results first posted: 2022-05-10 (ClinicalTrials.gov record NCT02060487, source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Bosnia & Herzegovina; Croatia; Czechia; Germany; Greece; Hong Kong SAR China; Israel; Latvia; Malaysia; Mexico; Poland; Romania; Russia; Serbia; Singapore; South Africa; Spain; Thailand; Türkiye; Ukraine (ClinicalTrials.gov record NCT02060487, source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02060487-2022-05-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effects of Oral Sildenafil on Mortality in Adults With PAH
- Acronym: AFFILIATE
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): sildenafil citrate
- Intervention (Drug): sildenafil citrate
- Intervention (Drug): sildenafil citrate
- Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (`cardio:org-pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension (`cardio:pubmed-38752352`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d55aeab5d41092732f6035d7ecfb7f591fdb843e38a082f66c73b493406efe52
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
